Superiority of Rituximab Over Mycophenolate Mofetil in the Treatment of Pemphigus Vulgaris: A Step Further in Its Approval as a First-Line Treatment?

被引：0
|
作者：
Lemieux, Alexandre [1 ]
Saber, Melissa [1 ]
Cote, Benoit [1 ]
机构：
[1] Ctr Hosp Univ Montreal, Serv Dermatol, Dept Med, 1000 Rue St Denis, Montreal, PQ, Canada
来源：
JOURNAL OF CUTANEOUS MEDICINE AND SURGERY | 2022年 / 26卷 / 01期
关键词：
pemphigus; rituximab; mycophenolate mofetil; treatment; THERAPY;
D O I：
10.1177/12034754211035098
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：103 / 104
页数：2
相关论文
共 50 条
  • [1] Rituximab as first-line treatment of pemphigus
    Schmidt, Enno
    LANCET, 2017, 389 (10083) : 1956 - 1958
  • [2] Mycophenolate Mofetil for First-Line Treatment of Immune Thrombocytopenia
    Bradbury, Charlotte A.
    Pell, Julie
    Hill, Quentin
    Bagot, Catherine
    Cooper, Nichola
    Ingram, Jenny
    Breheny, Katie
    Kandiyali, Rebecca
    Rayment, Rachel
    Evans, Gillian
    Talks, Kate
    Thomas, Ian
    Greenwood, Rosemary
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (10) : 885 - 895
  • [3] Mycophenolate mofetil and enteric-coated mycophenolate sodium in the treatment of pemphigus vulgaris and pemphigus foliaceus
    Doukaki, Spyridoula
    Platamone, Andrea
    Alaimo, Roberta
    Bongiorno, Maria Rita
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2015, 26 (01) : 67 - 72
  • [4] Successful treatment with mycophenolate mofetil of four Japanese patients with pemphigus vulgaris
    Koga, Hiroshi
    Ishii, Norito
    Hamada, Takahiro
    Karashima, Tadashi
    Nakama, Takekuni
    Yasumoto, Shinichiro
    Hashimoto, Takashi
    EUROPEAN JOURNAL OF DERMATOLOGY, 2010, 20 (04) : 472 - 475
  • [5] First-line Treatment of Pemphigus Vulgaris With a Combination of Rituximab and High-Potency Topical Corticosteroids
    Ingen-Housz-Oro, Saskia
    Valeyrie-Allanore, Laurence
    Cosnes, Anne
    Ortonne, Nicolas
    Huee, Sophie
    Paul, Muriel
    Wolkenstein, Pierre
    Chosidow, Olivier
    JAMA DERMATOLOGY, 2015, 151 (02) : 200 - 203
  • [6] Network meta-analysis-based comparison of first-line steroid-sparing adjuvants in the treatment of pemphigus vulgaris and pemphigus foliaceus
    Lee, Meng-Sui
    Yeh, Yi-Chun
    Tu, Yu-Kang
    Chan, Tom C.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (01) : 176 - 186
  • [7] Pediatric Pemphigus Vulgaris: Durable Treatment Responses Achieved with Prednisone and Mycophenolate Mofetil (MMF)
    Baratta, Andrea
    Camarillo, Diana
    Papa, Christine
    Treat, James R.
    Payne, Aimee S.
    Rozenber, Suzanne S.
    Yan, Albert C.
    PEDIATRIC DERMATOLOGY, 2013, 30 (02) : 240 - 244
  • [8] Rituximab exhibits a better safety profile when used as a first line of treatment for pemphigus vulgaris: A retrospective study
    Aryanian, Zeinab
    Balighi, Kamran
    Daneshpazhooh, Maryam
    Karamshahi, Emad
    Hatami, Parvaneh
    Goodarzi, Azadeh
    Tajalli, Mahroo
    Vance, Terrence M.
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2021, 96
  • [9] Mycophenolate mofetil as first-line treatment improves clinically evident early scleroderma lung disease
    Liossis, S. N. C.
    Bounas, A.
    Andonopoulos, A. P.
    RHEUMATOLOGY, 2006, 45 (08) : 1005 - 1008
  • [10] Rituximab in Membranous Nephropathy: Is It a First-Line Treatment?
    Appel, Gerald B.
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2012, 23 (08): : 1280 - 1282
12345